Article Link: FDA Approves Expanded Use of Vraylar (cariprazine) in the Treatment of Bipolar Depression DUBLIN and BUDAPEST, Hungary, May...
FDA Approves Zolgensma (onasemnogene abeparvovec-xioi) Gene Therapy to Treat Pediatric Patients with Spinal Muscular Atrophy
Article Link: FDA Approves Zolgensma (onasemnogene abeparvovec-xioi) Gene Therapy to Treat Pediatric Patients with Spinal Muscular Atrophy ...
FDA Approves Jakafi (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease
Article Link: FDA Approves Jakafi (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease WILMINGTON, Del.–...
FDA Approves Piqray (alpelisib) as First PI3K Inhibitor for Breast Cancer
Article Link: FDA Approves Piqray (alpelisib) as First PI3K Inhibitor for Breast Cancer May 24, 2019 — Today, the U.S. Food and Dru...
FDA Approves Sorilux for Adolescent Plaque Psoriasis
Article Link: FDA Approves Sorilux for Adolescent Plaque Psoriasis ADELAIDE, Australia, May 22, 2019 /PRNewswire/ — Mayne Pharma Gr...
FDA Approves Nayzilam (midazolam) Nasal Spray to Treat Seizure Clusters
Article Link: FDA Approves Nayzilam (midazolam) Nasal Spray to Treat Seizure Clusters Brussels (Belgium) & Atlanta, Georgia (U.S.) – ...
FDA Approves Gattex (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)
Article Link: FDA Approves Gattex (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS) Lexington, MA, May 1...
FDA Approves Fragmin (dalteparin sodium) as First Anticoagulant for Venous Thromboembolism in Pediatric Patients
Article Link: FDA Approves Fragmin (dalteparin sodium) as First Anticoagulant for Venous Thromboembolism in Pediatric Patients May 16, 20...
AbbVie Announces US FDA Approval of Venclexta (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients
Article Link: AbbVie Announces US FDA Approval of Venclexta (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic L...
FDA Approves Broadened Indication for Xeomin (incobotulinumtoxinA) as First-Line Treatment for Blepharospasm (Involuntary Blinking) in Adult Patients
Article Link: FDA Approves Broadened Indication for Xeomin (incobotulinumtoxinA) as First-Line Treatment for Blepharospasm (Involuntary Blinking) in A...
